- Email: [email protected]
4959320 Monoclonal antibody, process for preparing same, reagent for detecting cancer antigen containing the monoclonal antibody and process for preparing same
xvii
New Patents
4959320 MONOCLONAL ANTIBODY, PROCESS FOR PREPARING SAME, REAGENT FOR DETECTING CANCER ANTIGEN CONTAINING THE MONOCLONAL ANTIBODY AND PROCESS FOR PREPARING SAME Yahiro Uemura, Kazumi Fukuyama, Takashi Kobayashi, Yoshiaki Kanou, Ryutaro Yamana, Eiji Kashiwagi, Tomokun Taniguchi, Kazuaki Nakura, Masahiro Watanabe, Masayuki Nishida, Tadakazu Suyama, Osaka, Japan assigned to Green Cross Corporation A monoclonal antibody is described, having a specific reactivity with a cancer-associated antigen selected from pancreas cancer-associated antigen, intestinum crassum cancer-associated antigen and hepatoma-associated antigen and has the following characteristics: (1) it exists in a blood serum of pancreas cancer, intestinum crassum cancer and hepatoma patients; (2) it comprises glycoproteins; (3) it has a molecular weight of about 700,000 to 1,500,000, as measured by gel-filtration and determined by comparison with that of a known protein; (4) it has a maximum absorption of 2800 nm when dissolved in 0.1 M acetic acid buffer solution (pH 4.5); and (5) it is released at least in a cultured supernatant medium of establihed cell line of COLO-201, TE-1, TE-2, TE-3, NRC-12, M K N 45 and K A T O III. The monoclonal antibody is utilized as a reagent for detecting pancreas cancer, intestinum crassum cancer and hepatoma. A process for preparing the monoclonal antibody and a process for preparing the reagent are also disclosed.
4959323 PRODUCTION AND USE OF PRE S POLYPEPTIDES OF HEPATITIS B VIRUS George Acs, Judith K Christman, Peter Price, Wol Offensperger, Silke Wahl assigned to Mt Sinai School of Medicine of the City University of New York In accordance with the present invention, recombinant plasmids are described which, when inserted into microbial hosts, direct the
synthesis of proteins in which preS polypeptides found on the surface of human hepatitis B virus are fused to the enzyme beta-galactosidase. The recombinant plasmids are produced by inserting D N A sequences encoding the preS polypeptides into the lacZ gene, which codes for E. coli betagalactosidase, carried by the plasmids. Large amounts of the preS- beta-galactosidase fusion proteins can be isolated from microbial cultures carrying the recombinant plasmids. Antigenic determinants of fusion protein so produced are recognized by antibodies to the preS determinants of native hepatitis B virus. The betagalactosidase activity of such fusion protein is detected by a suitable chromogenic or fluorogenic substrate. PreS- beta-galactosidase fusion proteins so produced can be used in an enzyme-linked immunosorbent assay (ELISA) to diagnose the presence of hepatitis B virus infection. Additionally, the fusion proteins can be cleaved to release preS polypeptides which can be further purified. PreS polypeptides obtained from these fusion proteins can be used to immunize patients against hepatitis B virus.
4959361 TRIAZOLO(4,3-A)(1 4)BENZODIAZEPINES AND THIENO (3,2-F)(1 2,4)TRIAZOLO(4, 3-A)(1,4)DIAZEPINE COMPOUNDS WHICH HAVE USEFUL ACTIVITY AS PLATELET ACTIVATING FACTOR (PAF) ANTAGONISTS Armin Walser assigned to Hoffmann-La Roche Inc The invention relates to compounds of the formula See Patent f o r Chemical Structure I wherein X is -CH double bondCH- or S; R1 is lower alkyl, lower alkoxy or trifluoromethyl; R2 is hydrogen, lower alkyl, lower alkoxy, hydroxy or alkanoyloxy; R3 and R4, independently, are hydrogen, chlorine, fluorine, lower alkyl or lower alkoxy; s is an integer from 0 to 1, provided that when s is 1, R2 cannot be hydroxy, lower alkoxy or alkanoyloxy; R5 is a radical of the formula R6-(CH2)n- or R7-O-(CH2)m- wherein R6 and R7 are aryl or a heterocyclic radical, n is an integer of from 0 to 2 and m is an integer of from 1 to 2, provided that, when n is 0, R6 must be attached through a carbon to carbon bond, and provided that R7 is always attached through a carbon to oxygen bond, and, when at least one asymmetric carbon is present, its enantiomers and racemates, and pharmaceutically acceptable acid addition salts thereof. The compounds of
New Patents
4959320 MONOCLONAL ANTIBODY, PROCESS FOR PREPARING SAME, REAGENT FOR DETECTING CANCER ANTIGEN CONTAINING THE MONOCLONAL ANTIBODY AND PROCESS FOR PREPARING SAME Yahiro Uemura, Kazumi Fukuyama, Takashi Kobayashi, Yoshiaki Kanou, Ryutaro Yamana, Eiji Kashiwagi, Tomokun Taniguchi, Kazuaki Nakura, Masahiro Watanabe, Masayuki Nishida, Tadakazu Suyama, Osaka, Japan assigned to Green Cross Corporation A monoclonal antibody is described, having a specific reactivity with a cancer-associated antigen selected from pancreas cancer-associated antigen, intestinum crassum cancer-associated antigen and hepatoma-associated antigen and has the following characteristics: (1) it exists in a blood serum of pancreas cancer, intestinum crassum cancer and hepatoma patients; (2) it comprises glycoproteins; (3) it has a molecular weight of about 700,000 to 1,500,000, as measured by gel-filtration and determined by comparison with that of a known protein; (4) it has a maximum absorption of 2800 nm when dissolved in 0.1 M acetic acid buffer solution (pH 4.5); and (5) it is released at least in a cultured supernatant medium of establihed cell line of COLO-201, TE-1, TE-2, TE-3, NRC-12, M K N 45 and K A T O III. The monoclonal antibody is utilized as a reagent for detecting pancreas cancer, intestinum crassum cancer and hepatoma. A process for preparing the monoclonal antibody and a process for preparing the reagent are also disclosed.
4959323 PRODUCTION AND USE OF PRE S POLYPEPTIDES OF HEPATITIS B VIRUS George Acs, Judith K Christman, Peter Price, Wol Offensperger, Silke Wahl assigned to Mt Sinai School of Medicine of the City University of New York In accordance with the present invention, recombinant plasmids are described which, when inserted into microbial hosts, direct the
synthesis of proteins in which preS polypeptides found on the surface of human hepatitis B virus are fused to the enzyme beta-galactosidase. The recombinant plasmids are produced by inserting D N A sequences encoding the preS polypeptides into the lacZ gene, which codes for E. coli betagalactosidase, carried by the plasmids. Large amounts of the preS- beta-galactosidase fusion proteins can be isolated from microbial cultures carrying the recombinant plasmids. Antigenic determinants of fusion protein so produced are recognized by antibodies to the preS determinants of native hepatitis B virus. The betagalactosidase activity of such fusion protein is detected by a suitable chromogenic or fluorogenic substrate. PreS- beta-galactosidase fusion proteins so produced can be used in an enzyme-linked immunosorbent assay (ELISA) to diagnose the presence of hepatitis B virus infection. Additionally, the fusion proteins can be cleaved to release preS polypeptides which can be further purified. PreS polypeptides obtained from these fusion proteins can be used to immunize patients against hepatitis B virus.
4959361 TRIAZOLO(4,3-A)(1 4)BENZODIAZEPINES AND THIENO (3,2-F)(1 2,4)TRIAZOLO(4, 3-A)(1,4)DIAZEPINE COMPOUNDS WHICH HAVE USEFUL ACTIVITY AS PLATELET ACTIVATING FACTOR (PAF) ANTAGONISTS Armin Walser assigned to Hoffmann-La Roche Inc The invention relates to compounds of the formula See Patent f o r Chemical Structure I wherein X is -CH double bondCH- or S; R1 is lower alkyl, lower alkoxy or trifluoromethyl; R2 is hydrogen, lower alkyl, lower alkoxy, hydroxy or alkanoyloxy; R3 and R4, independently, are hydrogen, chlorine, fluorine, lower alkyl or lower alkoxy; s is an integer from 0 to 1, provided that when s is 1, R2 cannot be hydroxy, lower alkoxy or alkanoyloxy; R5 is a radical of the formula R6-(CH2)n- or R7-O-(CH2)m- wherein R6 and R7 are aryl or a heterocyclic radical, n is an integer of from 0 to 2 and m is an integer of from 1 to 2, provided that, when n is 0, R6 must be attached through a carbon to carbon bond, and provided that R7 is always attached through a carbon to oxygen bond, and, when at least one asymmetric carbon is present, its enantiomers and racemates, and pharmaceutically acceptable acid addition salts thereof. The compounds of